Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results
Open Access
- 6 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Radiation Oncology
- Vol. 16 (1), 1-11
- https://doi.org/10.1186/s13014-020-01731-z
Abstract
Particle radiotherapy has increasingly gained acceptance for locally advanced pancreatic cancers owing to superior tumor conformity and dosimetry compared to conventional photon radiotherapy. However, the close proximity of the pancreas to the stomach and duodenum leads to radiation-induced gastrointestinal toxicities, which hinder the delivery of curative doses to the tumor. To overcome this problem, a surgical spacer was placed between the tumor and gastrointestinal tract, and subsequent proton radiotherapy was performed in this study. Data from 9 patients who underwent surgical spacer placement and subsequent proton radiotherapy were analyzed. The safety and feasibility of the spacer placement surgery were evaluated; the impact of the spacer on dosimetry was also assessed using dose volume histogram (DVH) analyses, before and after surgical spacer placement. Surgical spacer placement and subsequent proton radiotherapy were successfully completed in all cases. Surgical spacer placement significantly improved the dose intensity covering 95%, mean, and minimum doses for the gross tumor volume, and the clinical and planning target volume based on the DVH, while respecting the dose constraints of the gastrointestinal tract. Based on the Common Terminology Criteria for Adverse Events, two patients (22.2%) developed gastrointestinal ulcer (Grade 2) at 1 and 35 months, and one patient (11.1%) developed gastric perforation (Grade 4) at 4 months after proton radiotherapy. Surgical spacer placement in the locally advanced pancreatic body and tail cancers is relatively safe and technically feasible. Comparing radiation plans, surgical spacer placement seems to improve the dose distribution in the locally advanced pancreatic body and tail cancers, which are close to the gastrointestinal tract.Keywords
This publication has 32 references indexed in Scilit:
- Preclinical investigations towards the first spacer gel application in prostate cancer treatment during particle therapy at HITRadiation Oncology, 2013
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group TrialJournal of Clinical Oncology, 2011
- Risk factors for survival and local recurrence after particle radiotherapy for single small hepatocellular carcinomaBritish Journal of Surgery, 2011
- Pancreatic CancerThe New England Journal of Medicine, 2010
- High‐dose proton therapy and carbon‐ion therapy for stage I nonsmall cell lung cancerCancer, 2010
- Surgical spacer placement and proton radiotherapy for unresectable hepatocellular carcinomaWorld Journal of Gastroenterology, 2010
- Particle beam radiotherapy with a surgical spacer placement for advanced abdominal leiomyosarcoma results in a significant clinical benefitJournal of Surgical Oncology, 2009
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO studyAnnals of Oncology, 2008
- Proton Therapy in Clinical Practice: Current Clinical EvidenceJournal of Clinical Oncology, 2007
- Current therapies and advances in the treatment of pancreatic cancerCritical Reviews in Oncology/Hematology, 2006